6 ISICEM News Thursday 22 March 2018 Issue 3 Issue 3 Thursday 22 March 2018 ISICEM News 7

Timing

Chest Imaging<sup>a</sup>

Origin of edema

Oxygenation<sup>b</sup>

Moderate

(barometric pressure/760)]



# Improved understanding of ARDS mechanism of disease may offer an opportunity to advance patient care

cute respiratory distress syndrome (ARDS) is a lifethreatening lung condition seen in intensive care units (ICUs), where fluid from surrounding blood vessels leaks through the endothelial barrier into the lungs. It is a complicated, heterogeneous condition associated with many different causes (e.g. pneumonia, sepsis and major trauma) that make it difficult to diagnose.

With such challenges, it is no wonder that ARDS is one of the key focal areas at the ISICEM meeting this year.

An estimated >300,000 people develop ARDS in the USA and EU annually.3 It is a major cause of death, with mortality rates 27-45%, and has long-term health and social implications for survivors, which can persist for at least five years.4-6 The physical impact of ARDS can also result in significant impairments to quality of life,4 with survivors reporting high rates of depression (17-43%), posttraumatic stress disorder (PTSD; 21-35%) and anxiety (23-48%). "While the primary focus in



ICUs is to save the life of the patient, in treating ARDS, we cannot ignore that different interventions can lead to long-term complications for the patient," Geoff Bellingan (Medical Director for Surgery and Cancer, specializing in

## **Diagnosing ARDS**

- ARDS is diagnosed based on the Berlin definition (Table 1): occurring within one week of known clinical insult, new or worsening respiratory symptoms; bilateral opacities not fully explained by effusions; lobar/lung collapse or nodules and respiratory failure not fully explained by cardiac failure or fluid overload (with objective assessment to exclude hydrostatic edema); and reduced oxygenation
- The severity of ARDS is then classified as follows: mild, 200 mmHg < PaO<sub>2</sub>/FlO<sub>2</sub> ≤300 mmHg with positive end-expiratory pressure (PEEP) or continuous positive airway pressure (CPAP) ≥5 cm H<sub>2</sub>O; moderate, 100 mmHg < PaO<sub>2</sub>/FlO<sub>2</sub> ≤200 mmHg with PEEP ≥5 cm H,O; and severe, PaO,/FIO, ≤100 mmHg with PEEP ≥5 cm H,O.¹ Historically, the phrase, 'acute lung injury (ALI)' has been used but this refers most commonly to the mild severity of ARDS<sup>2</sup>

"Since ARDS impacts people of all ages, in caring for ARDS you are saving the lives of both young and old." Geoff Bellingan

critical care at University College London Hospitals, London, UK), told ISICEM News ahead of his presentation today on the role of interferon-beta in ARDS.

"Some people will have persistent breathlessness that may recover with time. They may also experience polyneuropathy involving weight loss and weakening of the muscles. Furthermore, the psychological impact is another concern."

The complex and varying sequelae after critical illness, including cognitive, psychological and physical effects, have been described as post-intensive care syndrome, which affects many patients treated in the ICU, and increases with duration of stay.8 Therapies reducing the ICU length of stay will also help reduce these additional problems for patients.

### Significant economic burden for patients and hospitals

Therefore, it is not surprising that ARDS places a considerable economic burden on ICUs and hospitals. The average stay in the ICU is 25 days, and the average length of hospitalization is 47 days.9 In terms of economic burden, approximate UK costs for treating ARDS patients during their initial hospitalization and during the first year after their illness are £40-45,000 per patient,10 and the direct hospital costs from ARDS are estimated at approximately \$82,000.\*11

The impact on long-term quality of life also has economic implications, with depression and PTSD being significant factors affecting a

patient's ability to return to work and maintain employment

Commenting on the economic implications of treating ARDS effectively, Professor Bellingan explained that, "Since ARDS impacts people of all ages, in caring for ARDS you are saving the lives of both young and old. Saving young people means they can get back to work eventually. However, depression, anxiety and PTSD may be lessened by being in intensive care for a shorter period." These factors highlight the need for the development of an effective treatment for ARDS, a goal that has, so far, eluded researchers.

#### Failed trials of investigative compounds

Professor Bellingan referred to a multicenter, randomized, placebocontrolled trial of salbutamol for the treatment of ARDS, the so-called 'BALTI' study (The β-Agonist Lung Injury Trial).12

The BALTI study found that absorption of sodium via apical epithelial sodium channels (ENaC) is essential for fluid clearance in the lung; activation of ENaC is regulated by cyclic adenosine monophosphate (cAMP), and enhanced intracellular cAMP is stimulated by intravenous salbutamol that accelerates the resolution of alveolar edema. In their conclusions, the study authors wrote that, "The trial provides the first proof of principle that, in humans with ALI/ARDS, sustained treatment with intravenous  $\beta$ -agonists reduces extravascular lung water."

Yet, despite these results, the BALTI trial was stopped early due to harm. "β-2 agonists were tried - and improved the capillary leak - but had significant side effects in ARDS," said Professor Bellingan. "But new options exist and studies are ongoing. Targeting the capillary leak is still of interest.

"Compared with heart disease or cancer, ARDS occurrence is not that common, but in the specific field of critical care, it is common, and a key unmet medical need," Professor Bellingan pointed out.

"Given this situation, it's not easy to do a trial with 20,000 ARDS patients and show a 5% dif-

ference - you're looking for bigger percentage changes in a condition that is so variable," he added, outlining the difficulties in doing trial work in this field. "To add to the complications you have many variables as you're treating several different elements: capillary leak, fibrosis and inflammation." Setting these difficulties aside,

Table 1. The Berlin Definition of Acute Respiratory Distress Syndrome<sup>1</sup>

**Severe**  $PaO_2/FIO_2 \le 100 \text{ mm Hg with PEEP} \ge 5 \text{ cm H}_2O$ 

risk factor present

pressure of arterial oxygen; PEEP, positive end-expiratory pressure.

a Chest radiograph or computed tomography scan.

Acute Respiratory Distress Syndrome

Respiratory failure not fully explained by cardiac failure or fluid overload

**Mild** 200 mm Hg < PaO<sub>2</sub>/FIO<sub>2</sub>  $\le$  300 mm Hg with PEEP or CPAP  $\ge$ 5 cm H<sub>2</sub>Oc

100 mm Hg < PaO<sub>2</sub>/FIO<sub>2</sub>  $\le$  200 mm Hg with PEEP  $\ge$  5 cm H<sub>2</sub>O

Abbreviations: CPAP, continuous positive airway pressure; FIO2, fraction of inspired oxygen; PaO2, partial

1. Reproduced with permission from JAMA. 2012. 307(23):2526-33. Copyright@2018 American Medical Association. All rights reserved.

b If altitude is higher than 1000 m, the correction factor should be calculated as follows: [PaO<sub>d</sub>FIO<sub>2</sub> x

c This may be delivered noninvasively in the mild acute respiratory distress syndrome group.

Within one week of a known clinical insult or new or worsening respiratory symptoms

Need objective assessment (eg, echocardiography) to exclude hydrostatic edema if no

Bilateral opacities - not fully explained by effusions, lobar/lung collapse, or nodules

it is clear that we need novel approaches to managing ARDS. For Professor Bellingan, one area of interest could be the common issue of vascular leakage.

#### **Understanding mechanisms** driving ARDS

Researchers are beginning to make promising inroads into better understanding of the mechanisms that drive the occurrence of ARDS.4,13 Regardless of the etiology, all patients with ARDS have the same underlying problem, a compromised endothelial barrier that allows protein-rich fluid from surrounding blood vessels to leak into the lungs. This fluid impairs the absorption of oxygen into the blood stream, starving vital organs and leading to hypoxia.

Professor Bellingan explained further: "If the patient has edema, cellular enzymes and pores in the lungs try to re-absorb the fluid. It's not just a capillary leak, there will be inflammation - in ARDS these pathophysiological processes swamp the ability of the lung epithelium to clear that fluid.'

Research has elucidated some of the molecular mechanisms driving ARDS:

 Transport capacity of the alveolar epithelium is mark"ARDS is a heterogeneous condition with a variety of outcomes, and because of this it is not straightforward to provide a treatment. We need a drug that works on the inflammatory processes, capillary leakage processes and the thrombotic processes – all of which happen in ARDS."

Geoff Bellingan

edly diminished in ARDS and increasing severity is associated with higher mortality

- Excessive hydrostatic pressures and unfavorable ventilatory strategies exacerbate the prob-
- ARDS is associated with cellular inflammatory and immune responses, with accumulation of neutrophils, macrophages and red blood cells in the alveoli<sup>5,13</sup>
- Studies have shown that the en-

zyme, CD73 contributes to the maintenance of the endothelial barrier, reduces inflammation and increases fluid clearance, through generation of adeno-

The usual understanding of ARDS is to treat inflammation, but we need to look at other key problems, of which lung leakage is key, and which is a new approach," remarked Professor Bellingan

#### No licensed therapy for **ARDS** treatment

"ARDS is a heterogeneous condition with a variety of outcomes. and because of this it is not straightforward to provide a treatment," said Professor Bellingan. "We need a drug that works on the inflammatory processes, capillary leakage processes and the thrombotic processes – all of which happen in ARDS. If we can develop this, then it should help us reduce the high mortality rate, which is where we have been stuck for the past five years or more."

Patients are currently managed with mechanical ventilation to maintain their breathing and oxygen levels and provide the lungs with support to allow the body itself to rectify the vascular leakage. However, mechanical ventilation has the potential to cause further damage to the lungs and, therefore, needs to be carefully managed, with research ongoing to optimize its use, and reduce the damaging effects. However, if the opportunity that our greater understanding of the role of the endothelial barrier can be used to develop an effective treatment for ARDS, without undue side effects, it could significantly improve patient management, and ultimately outcomes, for those affected by this devastating syndrome.

Professor Bellingan's talk is one of a number of ARDS presentations that are taking place during today's 'Managing ARDS' session, being held in the Gold Hall between 13:45-17:00.

Calculated from the original Canadian dollar amount to US dollars based on the 2002 average exchange rate of 1.57 CAD

#### References

- ARDS Definition Taskforce. Acute respiratory distress syndrome: the Berlin Definition JAMA 2012;307:2526-33.
- injury and acute respiratory distress syndrome. J Emerg Trauma Shock 2010;3:43–51.
- Faron Pharmaceuticals data on American Thoracic Society.
- Breathing in America: Diseases, progress, and hope. Chapter 2: Acute Respiratory Distress Syndrome, 2010, Available at: https://www.thoracic.org/ patients/patient-resources/ breathing-in-america/resources/
- distress-syndrome.pdf. Last accessed February 2018.
- Rubenfeld GD, et al. Incidence and outcomes of acute ung injury. N Engl J Med 2005:353:1685-93 2. Ragaller M, Richter T. Acute lung
  - Cavalcanti AB, et al. Effect of lung recruitment and titrated Positive End-Expiratory Pressure (PEEP) vs low PEEP on mortality in patients with acute respira
  - 2017;318:1335-45. Davydow DS, et al. Psychiatric morbidity in survivors of the acute respiratory distress syndrome: a systematic review Psychosom Med 2008:70:512-
  - 8. Rawal G, et al. Post-intensive

- Care Syndrome: an overview. . Transl Int Med 2017;5:90-2. Herridge MS, et al. Functional disability 5 years after acute
- Engl J Med 2011;364:1293-304. 10. Lall R, et al. A randomised ontrolled trial and cost effectiveness analysis of high frequency oscillatory ven against conventional artificial ntilation for adults with acute respiratory distress syndrome The OSCAR (OSCillation in
- Assess 2015;19:1–177. 11. Herridge MS, et al. Recovery and outcomes after the acute espiratory distress syndrome (ARDS) in patients and their family caregivers. Intensive Car

ARDS) study. Health Techno

12. Perkins GD, et al. The betaagonist lung injury trial (BALTI): randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 2006:173:281-7

Med 2016;42:725-38.

- 13. Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and reatment. Annu Rev Pathol 2011:6:147-63.
- Grünewald JK. Ridley AJ. CD73 represses pro-inflammatory esponses in human endothelial cells. J Inflamm 2010:7:10.
- 15. Eckle T. et al. A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. Clin Invest 2008;118:3301-15.